Retrieved on:
Wednesday, February 21, 2024
COLUMBUS, Ohio, Feb. 21, 2024 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today welcomed Dr. Rahul Gupta, Director of the White House Office of National Drug Control Policy (ONDCP), to its Columbus, Ohio manufacturing facility for a visit and important dialogue on the US opioid overdose epidemic and Hikma's and ONDCP's shared goal of expanding the availability and awareness of life-saving naloxone.
Key Points:
- COLUMBUS, Ohio, Feb. 21, 2024 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today welcomed Dr. Rahul Gupta, Director of the White House Office of National Drug Control Policy (ONDCP), to its Columbus, Ohio manufacturing facility for a visit and important dialogue on the US opioid overdose epidemic and Hikma's and ONDCP's shared goal of expanding the availability and awareness of life-saving naloxone.
- During the visit, Dr. Gupta met with Hikma employees and toured the Columbus facility, observing firsthand the production of Hikma's overdose reversal medicine KLOXXADO® (naloxone HCl) nasal spray 8mg.
- "In his Unity Agenda, President Biden set a clear directive: we must all come together to address the nation's overdose epidemic," said White House Office of National Drug Control Policy (ONDCP) Director Dr. Rahul Gupta.
- "Hikma firmly believes that no one who needs overdose reversal medicine should lack access because of costs, awareness or availability.
AFT,
NSAID,
Patient,
Pain,
Paracetamol,
Pain management,
Hikma Pharmaceuticals,
Ibuprofen,
Health,
Hospital,
Pharmaceutical industry LONDON, Feb. 5, 2024 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the launch of COMBOGESIC® IV (acetaminophen and ibuprofen) injection in the US.
Key Points:
- LONDON, Feb. 5, 2024 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the launch of COMBOGESIC® IV (acetaminophen and ibuprofen) injection in the US.
- COMBOGESIC® IV is an intravenous, opioid-free pain relief medicine that is a combination of 1,000 mg of acetaminophen and 300 mg of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID).
- In 2021, Hikma signed an exclusive license and distribution agreement with AFT Pharmaceuticals (AFT) for the commercialization of COMBOGESIC® IV in the US.
- Under the trade name of MAXIGESIC® IV outside of the United States, COMBOGESIC® IV is licensed in over 100 countries and marketed in over 20 countries.
Tragedy Assistance Program for Survivors,
The Washington Post,
White House,
Partnership,
Naloxone,
Office of National Drug Control Policy,
State government,
Medicine,
School,
Community,
Patient,
Policy,
Pharmaceutical industry,
Hikma LONDON, Oct. 3, 2023 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that on the two-year anniversary of its launch, it has now donated more than 375,000 doses of KLOXXADO® (naloxone HCl) nasal spray 8mg in the US – an important milestone in its ongoing work to help combat the opioid overdose epidemic.
Key Points:
- With the help of more than 40 donation partners, KLOXXADO® has been distributed for free in places it can have the biggest impact, including music festivals, downtowns and schools.
- "Since its launch two years ago, KLOXXADO® has quickly become an essential tool for those on the front lines working to reverse opioid overdoses and save lives," said Brian Hoffmann, President, Hikma Generics.
- Furthering its partnership with Remedy Alliance through a first-of-its-kind agreement for Hikma to provide a private label, discounted naloxone injectable medicine specifically for the harm reduction community.
- Ensuring widespread access to KLOXXADO® by providing a Co-Pay Assistance Program for eligible individuals, further increasing access and decreasing out-of-pocket costs to this life-saving medication.
Partnership,
Octave,
Approximation error,
Multiple sclerosis,
MS,
Alzheimer's disease,
Parkinson's disease,
HIV disease progression rates,
Patient,
Physician,
Medicine,
Health,
Disease,
Pharmaceutical industry LONDON, July 26, 2023 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that its venture capital arm, Hikma Ventures , has invested in Octave Bioscience , the developer of a first-of-its-kind platform to accurately and objectively measure and help manage complex and high-cost neurodegenerative diseases, starting with multiple sclerosis (MS).
Key Points:
- LONDON, July 26, 2023 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that its venture capital arm, Hikma Ventures , has invested in Octave Bioscience , the developer of a first-of-its-kind platform to accurately and objectively measure and help manage complex and high-cost neurodegenerative diseases, starting with multiple sclerosis (MS).
- "There is an immense unmet need within the MS space with outdated diagnostic tools, a lack of technological advancement, and limited support in addressing neurodegenerative diseases.
- "By offering an end-to-end solution which optimizes and personalizes care, Octave is revolutionising the way MS is treated and managed.
- Octave Bioscience will use the proceeds to support their commercialization efforts in MS and to explore expansion opportunities into other neurodegenerative diseases such as Parkinson's and Alzheimer's.
LONDON, June 15, 2023 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has launched Dobutamine Injection, USP, in a 250mg/20mL vial in the US.
Key Points:
- LONDON, June 15, 2023 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has launched Dobutamine Injection, USP, in a 250mg/20mL vial in the US.
- With this launch, Hikma's growing US portfolio of sterile injectable medicines now exceeds 150 products spanning a wide range of therapeutic areas and dosage forms.
- "Our portfolio of more than 150 injectable medicines has expanded by more than 50 percent over the last three years1, driven by customer needs, an expansion of our capabilities and product offerings, and the continued recognition of Hikma as a reliable, high-quality supplier of sterile injectable medicines," said Riad Mishlawi, President, Injectables, Hikma.
- In addition to its growing US portfolio, Hikma now markets approximately 30 sterile injectable medicines in Canada , with plans to launch up to 13 additional products this year.
LONDON, March 9, 2023 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the launch of four new sterile injectable medicines in Canada, providing important new treatment options for patients and health care providers, and building on the company's growing presence in the Canadian market.
Key Points:
- LONDON, March 9, 2023 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the launch of four new sterile injectable medicines in Canada, providing important new treatment options for patients and health care providers, and building on the company's growing presence in the Canadian market.
- The products being launched are:
With these launches, Hikma now markets approximately 30 different sterile injectable medicines in Canada, with plans to launch up to 13 additional sterile injectable products in Canada this year.
- "The launch of these new sterile injectable medicines is a significant step forward in growing our business in Canada and provides important new treatment options for patients and health care providers."
- "The expansion of our sterile injectable business in Canada continues the strong momentum of our Injectables business globally and builds on our position as a leading supplier of injectable medicines to US hospitals with a reputation for quality and reliability," said Riad Mishlawi, President, Injectables, Hikma.
Measles,
Dow Jones,
Treatment,
Biologic,
OTC,
National Institute,
Generic,
Social media,
Nose,
MENA,
Recurrence,
Asthma,
Virus,
Social,
Skin,
Infection,
Multimedia,
Thought,
SAR,
Ethics in pharmaceutical sales,
Breast milk,
Immune system,
Allergic rhinitis,
Allergy,
Fungus,
DJSI,
BSE,
Risk,
Tuberculosis,
Dermatology,
Taste,
Health,
Bacteria,
Pregnancy,
Patient,
Pharmaceutical industry,
Petroleum jelly,
Birth control,
Wood drying LONDON and MAHWAH, N.J.and MUMBAI, India, Aug. 30, 2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical company, and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), an innovation driven global pharmaceutical company, announced the launch of RYALTRIS™ (olopatadine hydrochloride and mometasone furoate nasal spray) in the US. RYALTRIS™ is approved by the US Food and Drug Administration (FDA) for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and pediatric patients 12 years of age and older. This launch builds upon Hikma's leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US.
Key Points:
- For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them.
- We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world.
- Ryaltris should not be used by anyone who has had an allergic reaction to olopatadine or mometasone.
- Ryaltris should be used under close medical supervision in anyone who has had nose bleeds or nasal perforation.
Calcitonin,
Achievement,
ANDA,
Federal Trade Commission,
Hospital,
Patient,
Salmon,
CGT,
Hikma Pharmaceuticals,
FDA,
Acquisition,
Water Street,
Pharmaceutical industry,
Hikma LONDON, April 21, 2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces that it has completed its acquisition of Custopharm Inc. ('Custopharm') from Water Street Healthcare Partners ('Water Street'), following approval from the US Federal Trade Commission.
Key Points:
- LONDON, April 21, 2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC(Hikma),the multinational pharmaceutical company, today announces that it has completed its acquisition of Custopharm Inc. ('Custopharm') from Water Street Healthcare Partners ('Water Street'), following approval from the US Federal Trade Commission.
- As previously announced on 27 September 2021, Hikma has acquired Custopharm for an initial cash consideration of $375 million on a debt and cash-free basis, with a further $50 million in contingent consideration payable upon the achievement of certain commercial milestones.
- Hikma is the second-largest supplier by volume of generic sterile injectable medicines used by US hospitals and health care providers.
- I am excited to welcome the team at Custopharm to Hikma as we continue to grow and strengthen our Injectables business."
Tact,
List of life sciences,
Organization,
HCPS,
Artificial intelligence,
CRM,
Industry,
Technology,
Calendar,
Knowledge,
Salesforce,
Investment,
Patient,
CEO,
Sales,
Management LONDON, March 29, 2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that its venture capital arm, Hikma Ventures has invested in Tact.ai , the customer engagement company for life sciences.
Key Points:
- LONDON, March 29, 2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that its venture capital arm, Hikma Ventures has invested in Tact.ai , the customer engagement company for life sciences.
- The investmentis the fourth Life Sciences industry investment in the past six months for Tact.ai, following its $33 million USD fundraise last year .
- Founded by former Salesforce.com executive,Chuck Ganapathi, Tact's customer engagement platform is designed for life sciences companies to take a holistic, outcome-centric approach to how they engage customers across all channels: face-to-face, phone, email, video, chat, and self-service.
- Tact.ai will use the proceeds to support further expansion with leading pharma companies and to continue building the industry's most customer-friendly engagement platform.
The investment is an extension of the Series B round that was previously announced by Activ Surgical in September 2021.
Key Points:
- The investment is an extension of the Series B round that was previously announced by Activ Surgical in September 2021.
- This most recent financing, which also saw participation from existing investors, brings the total Series B round to $60 million USD.
- Activ Surgical aims to revolutionize access to surgical care, enabling a future of augmented reality (AR)-based and artificial intelligence (AI)-driven surgery that is safe, smart, and accessible to all.
- We look forward to working with the talented Activ Surgical team to help them expand the global reach of their innovative platform to different geographies, especially the Middle East."
